
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Click the title above for a link to open the Pharmaceutical Executive May 2024 issue in an interactive PDF format.
over 2 years ago
'Patients are Waiting'over 2 years ago
Today’s New Messaging Mix: The State of Pharma Marketing in 2024over 2 years ago
Patient Treatment & Travel: The Need for Stepped-Up Supportover 2 years ago
A Biosimilars Roadmap: Understanding Payer Perceptionsover 2 years ago
Avoiding the Digital Age is Hurting Research Effortsover 2 years ago
Biotech’s Road to Recovery Takes a Wobbly Turnover 2 years ago
Yvonne Greenstreet: Answering the Call





